Related Experiment Video
Updated: Dec 18, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Abstract:
Autologous T cells engineered to target the MAGE-A4 cancer testis antigen successfully shrank a wide range of solid tumors with a manageable toxicity profile. In a phase I trial, the therapy, ADP-A2M4, showed the most promise in synovial sarcoma, yielding a disease control rate of around 90%.
Insights
Engineered T cells targeting MAGE-A4 cancer antigens show promise against solid tumors. This immunotherapy, ADP-A2M4, demonstrated significant tumor shrinkage and manageable side effects in early trials.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Solid tumors present significant treatment challenges.
- Cancer testis antigens like MAGE-A4 are potential therapeutic targets.
- Autologous T cell therapy offers a personalized approach to cancer treatment.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...

